Covis Pharma Holdings S.a.r.l.
12 articles with Covis Pharma Holdings S.a.r.l.
Makena currently remains on the market but is poised to be removed pending the outcome of the meeting.
March of Dimes, the nation’s leading nonprofit fighting for the health of moms and babies, announced that Covis Pharma Group is joining the effort. Covis Pharma will be the Presenting Sponsor at all March of Dimes events in Massachusetts in 2021 and 2022, including the Massachusetts March for Babies, the Lawn Party, the Black Ties for Babies Gala, the Signature Chef’s Event, and the Falmouth Road Race. “This partnership will have a major imp
Covis Group S.à r.l. announced the completion of its acquisition of AMAG Pharmaceuticals, Inc. through the successful tender offer for all of the outstanding shares of common stock of AMAG at $13.75 per share in cash and subsequent merger.
Covis Pharma B.V. Initiates Phase 3 Clinical Trial of Alvesco (Ciclesonide) Inhaler for the Treatment of COVID-19
U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) filing to study the use of Alvesco in COVID-19 Study will evaluate the Safety and Efficacy of Alvesco in the Treatment of Non-hospitalized COVID-19 Patients Aged 12 and Above
4/24/2020Biopharma and life sciences companies bolster their leadership teams and boards with this week's Movers & Shakers.
Covis Pharma, a global specialty pharmaceutical company, today announced the appointment of Rajiv De Silva as the Chairman of the Board of Directors, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200420005414/en/ Rajiv De Silva Joins Covis Pharma as Chairman of the Board of Directors (Photo: Business Wire) De Silva is a proven b
11/14/2018Two weeks after reporting a 45 percent growth in revenue for the third quarter, compared to last year, Swedish Orphan Biovitrum AB (Sobi) has snapped up the U.S. rights to AstraZeneca’s respiratory drug, Synagis, a drug used to treat RSV in infants, for $1.5 billion.
AstraZeneca is unloading rights to Alvesco (ciclesonide) to treat persistent asthma, and Omnaris and Zetonna (ciclesonide) to treat nasal symptoms associated with rhinitis. The company indicates that the rights cover markets outside the United States and the U.S. royalties for the drugs.
Concordia Healthcare Announces Completion Of Acquisition Of Covis Pharma Commercial Assets For U.S. $1.2 Billion